Activity of *Plasmodium vivax* promoter elements in *Plasmodium knowlesi*, and a centromere-containing plasmid that expresses NanoLuc throughout the parasite life cycle

Roberto R. Moraes Barros^{a,b,#}, Kittisak Thawnashom^{c,d}, Tyler J. Gibson^a, Jennifer S. Armistead^{a,e}, Ramoncito L. Caleon^a, Miho Kaneko^{c,f}, Whitney A. Kite^a, J. Patrick Mershon^a, Jacqueline K. Brockhurst^a, Theresa Engels^g, Lynn Lambert^h, Sachy Orr-Gonzalez^h, John H. Adams^e, Juliana M. Sá^a, Osamu Kaneko^c, Thomas E. Wellems^a

a: Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

b: Departamento de Microbiologia, Imunologia e Parasitologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil

c: Department of Protozoology, Institute of Tropical Medicine (NEKKEN), Nagasaki University, Nagasaki, Japan

d: Department of Medical Technology, Faculty of Allied Health Sciences, Naresuan University, Phitsanulok, Thailand

e: Center for Global Health and Infectious Diseases Research, College of Public Health, University of South Florida, Tampa, FL, USA

f: Department of Molecular Microbiology and Immunology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan

g: Division of Veterinary Research, National Institutes of Health, Bethesda, MD, USA

h: Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

Running title: A bioluminescent *Plasmodium knowlesi* line for research

Corresponding author: moraes.barros@unifesp.br

Abstract

Background: *Plasmodium knowlesi* is now the major cause of human malaria in Malaysia, complicating malaria control efforts that must attend to the elimination of multiple *Plasmodium* species. Recent advances in the cultivation of *P. knowlesi* erythrocytic-stage parasites *in vitro*, transformation with exogenous DNA, and infection of mosquitoes with gametocytes from culture have opened up studies of this pathogen without the need for resource-intensive and costly non-human primate (NHP) models. For further understanding and development of methods for parasite transformation in malaria research, this study examined the activity of various trans-species transcriptional control sequences and the influence of *Plasmodium vivax* centromeric (*pvcen*) repeats in plasmid-transfected *P. knowlesi* parasites.

Methods: *In vitro* cultivated *P. knowlesi* parasites were transfected with plasmid constructs that incorporated *P. vivax* or *Plasmodium falciparum* 5' UTRs driving the expression of bioluminescence markers (firefly luciferase or Nanoluc). Promoter activities were assessed by bioluminescence, and parasites transformed with human resistant allele dihydrofolate reductase-expressing plasmids were selected using antifolates. The stability of transformants carrying *pvcen*-stabilized episomes was assessed by bioluminescence over a complete parasite life cycle through a rhesus macaque monkey, mosquitoes, and a second rhesus monkey.

Results: Luciferase expression assessments show that certain *P. vivax* promoter regions, not functional in the more evolutionarily-distant *P. falciparum*, can drive transgene expression in *P. knowlesi*. Further, *pvcen* repeats may improve the stability of episomal plasmids in *P. knowlesi* and support detection of NanoLuc-expressing elements over the full parasite life cycle from rhesus macaque monkeys to *Anopheles dirus* mosquitoes and back again to monkeys. In assays of drug responses to chloroquine, G418 and WR9910, antimalarial half-inhibitory concentration (IC₅₀) values of blood stages measured by NanoLuc activity proved comparable to IC₅₀ values measured by the standard SYBR Green method.

Conclusion: All three *P. vivax* promoters tested in this study functioned in *P. knowlesi* whereas two of the three were inactive in *P. falciparum*. NanoLuc-expressing, centromere-stabilized plasmids may support high-throughput screenings of *P. knowlesi* for new antimalarial agents, including compounds that can block the development of mosquito- and/or liver-stage parasites.

Keywords: heterologous transfection, transgenic parasites, genetic transformation, luciferase expression, *in vitro* growth assays, antimalarial drug response assays

Background

Plasmodium knowlesi, once thought to infect macaques almost exclusively, is now a major cause of human malaria in Malaysia (1). Up to 10 % of *P. knowlesi* human infections cause severe malaria, leading to death in 1-2% of those afflicted (2). Increased prevalence of *P. knowlesi* infections represents an additional challenge to malaria elimination, especially in Southeast Asia, where *Plasmodium falciparum* and *Plasmodium vivax* infections are in decline (3,4). In some regions endemic to multiple *Plasmodium* species, malaria control work was found to decrease the prevalence of *P. falciparum* but did not produce comparable decreases of *P. vivax* or *P. knowlesi* (3–5).

In the 1970s, laboratory research on *P. falciparum* was boosted by the development of *in vitro* cultivation methods (6,7). However, similar long-term cultivation of any other human malaria species was unavailable until the adaptation of *P. knowlesi* parasites to culture (8,9). As with *P. falciparum*, transfection methods and the ability to infect mosquitoes with cultivated *P. knowlesi* parasites followed (8–11), and these are supporting new experimental studies without the need for resource-intensive and costly non-human primate (NHP) models. Fundamental biological differences between the *Plasmodium* species and factors affecting malaria control that are now more accessible to investigation include: the period of the intraerythrocytic life cycle (24 h for *P. knowlesi* vs. 48 h for *P. falciparum*) (12,13); features of host cell preference and cell invasion mechanisms (14–16); gametocyte development and transmission to mosquitoes (17); and antimalarial drug responses and mechanisms of resistance (18,19).

Transfection and genetic transformation of malaria parasites with various bioluminescent proteins have been used for *in vivo* studies of the traversal and tissue invasion of sporozoites injected in mammalian hosts by mosquitoes (20); functional analyses of promoters and introns (21–25); screens for candidate anti-malarials and inhibitors of parasite growth (26–28); and evaluations of compounds that block parasite infectivity to mosquitoes (29). This report presents investigations of exogenous transcriptional control sequences in transfected *P. knowlesi* parasites. Results show that *P. knowlesi* parasites can recognize *P. vivax* promoters that are poorly recognized by *P. falciparum* parasites; further, *P. vivax* centromeric (*pvcen*) repeats can improve the stability of transgenic plasmids across the complete parasite life cycle of *P. knowlesi* in rhesus monkeys and *Anopheles dirus* mosquitoes.

Methods

Parasites and culture

P. falciparum parasites were maintained in human red blood cells (hRBCs) purchased from Interstate Blood Bank (Memphis, TN, USA). *P. knowlesi* parasites were cultivated in rhesus red blood cells (rRBCs) as described (10); blood samples were obtained according to the National Institutes of Health (NIH) Guidelines for Animal Care and Use, under an Animal Study Proposal (ASP) approved by the National Institute of Allergy and Infectious Diseases (NIAID) Animal Care and Use Committee (ACUC); rhesus blood was processed and plasma was removed as described (10).

Cryopreserved stocks of a *P. falciparum* 3D7 clone (30) and the *P. knowlesi* H strain (31) were obtained from NIH inventory and thawed by standard methods (32). *Plasmodium falciparum* cultures were propagated in *P. falciparum* complete RPMI (PF-cRPMI) consisting of RPMI-1640 (KD Medical, Columbia, MD, USA) supplemented with 25 mM HEPES, 50 µg/mL hypoxanthine, 0.21% sodium bicarbonate, 20 mg/L gentamicin, and 1% Albumax II (Life Technologies, Carlsbad, CA, USA). *Plasmodium knowlesi* cultures were maintained in *P. knowlesi* complete RPMI (PK-cRPMI), consisting of RPMI-1640 supplemented with 25 mM HEPES, 50 µg/mL hypoxanthine, 0.26% sodium bicarbonate, 10 mg/L gentamicin (KD Medical), and 1% Albumax II (32). Cultures were maintained with RBCs up to 5% hematocrit, under a 90% N₂/5% CO₂/5% O₂ gas mixture at 37°C with daily media changes. Parasite development and propagation across the asexual blood-stage cycle were monitored by microscopy of thin blood films after fixation in methanol and staining for 15 min with 20% Giemsa's solution (Sigma-Aldrich, St. Louis, MO, USA). Parasitemia was estimated by counting the number of parasitized RBCs (pRBCs) per 1,000 RBCs. Cultures were maintained at parasitemias between 0.5 and 10%.

Rhesus infection using blood-stage *P. knowlesi*

Rhesus macaques (*Macacca mulatta*) were obtained from NIH-approved sources and housed in compliance with the Animal Welfare Act and the Guide for the Care and Use of Laboratory Animals (ILAR, 1996). All animal care and use in this study were performed in

accordance with the NIH Animal Research Advisory Committee (NIH ARAC) Guidelines, under ASP protocols approved by the NIAID ACUC.

Animals were anesthetized intramuscularly (IM) with 10 mg/kg ketamine to allow infection by mosquito bites or by intravenous (IV) inoculation of cultivated blood stage parasites. For the IV inoculation, a culture sample containing $\sim 2 \times 10^8$ parasitized rRBCs was pelleted by centrifugation (700 x g, 3 minutes). Pelleted cells were washed with 10 mL sterile and pure RPMI-1640, and resuspended to 1.5 mL volume of the same medium. After infection, parasitemia was checked daily by Giemsa-stained thin blood films as described above.

Plasmodium knowlesi infections were cured with three daily administrations of oral chloroquine (total dose: 50 mg/kg body weight). Thin and thick blood films were checked up to 30 days after treatment to confirm cure.

Mosquito feedings and assessment of oocysts and sporozoites

Mosquito feedings were performed using 3 – 5-day-old female *Anopheles. dirus* B and *An. dirus* (X strain) mosquitoes (31) raised in the LMVR/NIAID insectary. Mosquitoes were starved for 24 h in secure pint containers with up to 100 female mosquitoes per container. Feedings were performed at night (12:00 AM), as recommended for *P. knowlesi* transmission (12). Two pints of mosquitoes were used in each experiment, and mosquitoes were allowed to feed through a double safety net (bridal veil) for ~ 20 min directly onto the inner arm or thighs of the anesthetized rhesus macaque. Fed mosquitoes were maintained

with 10% corn syrup in water at 26°C for up to 18 days in the LMVR human malaria-secure insectary.

Mosquitoes were randomly selected and dissected 6 – 9 days post-feeding and examined for oocysts in the midgut; additional mosquitoes were randomly selected and dissected after 10 days to examine for sporozoites in the salivary glands. To assess oocyst presence and number, midguts from 16 – 20 dissected mosquitoes per container were stained with 0.05% mercurochrome for 10 min and then examined under the microscope (20× – 40× objective lens). Individual mosquito midguts containing oocysts were transferred to 1.5 mL tubes and used for NanoLuc assays. Sporozoites isolated from dissected salivary glands were combined and counted using a hemocytometer under the microscope at 40× magnification. The sporozoites were transferred to 1.5 mL tubes and used for NanoLuc assays. Remaining infected mosquitoes were used 14 days post-feeding to transmit parasites to an uninfected rhesus macaque as described above.

Plasmids

Plasmid pD-pfcam-Luc (10) contains the *fLuc* (firefly luciferase) cassette under control of a 0.6 kb 5′ untranslated region (UTR) from *P. falciparum calmodulin* (*pfcam*) and a 0.8 kb 3′ UTR sequence from *P. falciparum heat shock protein 86* (*pfhsp86*). pD-pfcam-Luc also contains the *hdhfr* cassette under control of a 0.6 kb 5′ UTR from *Plasmodium chabaudi dhfr-ts* (*pcdts* 5′), and a 0.8 kb 3′ UTR from *P. falciparum histidine rich protein 2* (*pfhrp2*) (**Fig 1**).

P. vivax and *P. knowlesi* 5' UTR sequences were amplified from genomic DNA of *P. vivax* NIH-1993 (33) or *P. knowlesi* H strains using the primers listed in Supplementary Table 1. Amplified sequences of 0.7 kb from the *P. vivax calmodulin (pvcam)* 5' UTR, 0.9 kb of the *P. vivax chloroquine resistance transporter (pvcrt)* 5' UTR, 1.4 kb of the *P. vivax heat shock protein 70 (pvhsp70)* 5' UTR, and 0.6 kb of the *P. knowlesi elongation factor-1 alpha (pkef1-alpha)* 5' UTR were isolated from agarose gels and cloned into the pGEM-T vector (Promega, Madison, WI, USA). To replace the *pfcam* 5' UTR sequence that drives *luciferase* transcription in the pD-pfcam-Luc, the pGEM-T clones of the *pvcam*, *pvcrt*, and *pvhsp70* 5' UTRs were digested using *BlpI* and *SpeI* restriction enzymes (New England Biolabs, Ipswich, MA), and agarose gel-purified fragments were subcloned into the plasmid pD-pfcam-Luc also digested with these enzymes. Resultant plasmids were named pD-pvcam-Luc, pD-pvcrt-Luc and pD-pvhsp70-Luc. To replace the *P. chabaudi dhfr-ts* 5' UTR that drives the *hdhfr* transcription in the pD-PfCam-Luc, the pGEM-T clones of the *pvhsp70* and *pkef1-alpha* 5' UTRs were digested using *BlpI* and *NcoI*, and the resulting fragments were cloned into the plasmid previously digested with the same enzymes, thus generating *pvhsp70D-pfcam-Luc* and *pkef1D-pfcam-Luc*.

Plasmid *pvcen-pvhsp70-D-NanoLuc* was developed from pDST-PvCEN11S3, pENT41-PvHSP70-5U-1k, pENT12-hDHFR, and pENT23-NLuc by MultiSite Gateway LR reaction (Invitrogen, Carlsbad, CA, USA) (34). pENT23-NLuc was generated by Gateway BP reaction between pDONR P2R-P3 plasmid (Invitrogen) and a DNA fragment encoding NanoLuc Luciferase amplified from pNL1.1 (NanoLuc) vector (Promega) with primers Nluc.B2F and Nluc.B3R (**Supplementary Table 1**). The plasmid contains the centromeric sequences of *P.*

vivax chromosome 11 and harbors a 1 kb 5' UTR sequence from the *P. vivax* *heat shock protein* driving the expression of a hdhfr-NanoLuc fusion cassette (**Fig 1**). The plasmid also contains 800 bp of the 3' UTR sequence from the *Plasmodium berghei* bifunctional dihydrofolate reductase-thymidylate synthase gene.

Parasite transformation

Parasites were transformed by the spontaneous DNA uptake method as described (10,35). Briefly, 300 μ L of pelleted rhesus RBCs were washed twice by centrifugation and resuspended in 5 mL cytomix (120 mM KCl, 0.15 mM CaCl₂, 2 mM EGTA, 5 mM MgCl₂, 10 mM K₂HPO₄/KH₂PO₄, 25 mM Hepes, pH adjusted to 7.6 with KOH). The RBCs were recovered and mixed with 100 μ L of cytomix containing 40 μ g of plasmid DNA, and transferred to a 0.2 cm electroporation cuvette (Bio-Rad, Hercules, CA, USA). Uninfected RBCs were electroporated in a Bio-Rad Gene Pulser II at 310 V and 975 μ F, with resulting time constants of 20-35 msec. The plasmid-loaded RBCs were washed twice with 5 mL of incomplete RPMI (cRPMI without Albumax II) and used immediately. Plasmid-loaded RBCs were added to 10 mL of PK-cRPMI in a 25 cm² flask. A 50 μ L suspension of 3% asynchronous pRBCs at 5% hematocrit was added to the flask for a final parasitemia of 0.5%. After 24 h in culture, fresh plasmid-loaded RBCs were again added to the flask for *P. knowlesi* transfections. After 72 h in culture, cells were collected for luciferase assays and/or continued in culture under 1 nM WR99210 pressure (WR99210 kindly supplied by Jacobus Pharmaceuticals Co., Inc.).

Luciferase assays

The fLuc and NanoLuc enzymatic assays were performed using blood- and mosquito-stage parasites. To remove hemoglobin from RBCs and avoid a possible quenching effect of luciferase assay signal, RBCs were treated with saponin: up to 250 μ L of packed RBCs were pelleted from cultures by centrifugation ($800\times g$, 3 min), overlying supernatant culture medium was removed, and the cells were twice suspended and re-pelleted in 1,000 μ L of 0.15% saponin in PBS (10 mM PO_4^{3-} , 137 mM NaCl, 2.7 mM KCl). After washing twice with 1 mL of PBS, the parasites were pelleted, resuspended in 50 μ L (fLuc assays) or 100 μ L (NanoLuc assays) of 1 $\times$ Cell Culture Lysis Reagent (Luciferase Assay System; Promega) and incubated for 10 min at room temperature. The resulting lysate was centrifuged for 1 min at $10,600\times g$ and the supernatant (20 μ L upper liquid layer) was used for the enzymatic reaction.

Midguts containing *P. knowlesi* oocysts were isolated from *Anopheles* mosquitoes. Each isolated midgut was re-suspended in 20 μ L of PBS, mixed with 80 μ L of Passive Lysis Buffer (Promega) and incubated for 10 min at room temperature for cell lysis. The lysate was centrifuged for 1 min at $10,600\times g$ and the supernatant (upper liquid layer) was used for the NanoLuc assays. Sporozoites isolated from 8 salivary gland pairs were combined and re-suspended in 40 μ L of PBS. The sporozoites were mixed with 60 μ L of Passive Lysis buffer and incubated for 10 min at room temperature for cell lysis. After centrifugation (1 min at $10,600\times g$) the supernatant was diluted 10-fold in Passive Lysis Buffer and the dilution was utilized for NanoLuc assays.

Firefly luciferase assays were performed using the Luciferase Assay System (Promega) following manufacturer's instructions. For this assay, 20 μ L of the lysate supernatant was mixed with 100 μ L of Promega Luciferase Assay Reagent and luminescence was assessed with a GloMax 20/20 Luminometer (10 sec integration time). NanoLuc assays were performed using the Nano-Glo Luciferase Assay System (Promega) following manufacturer's instructions. For the enzymatic reaction, 40 μ L of the lysate supernatant were mixed with the same volume of Nano-Glo reaction solution (Promega), incubated for 3 min at room temperature, and assessed with a GloMax 20/20 Luminometer (1 sec integration time). Measurements were collected in technical duplicates and averaged for analysis.

Quantitative Real-Time PCR

Quantitative real-time PCR (qPCR) reactions to evaluate plasmid copy number were performed using the Rotor-Gene SYBR Green PCR Kit according to manufacturer's instructions (Qiagen, Hilden, Germany). For each reaction a total of 50 ng of genomic DNA and 200 nM of each oligonucleotide primer were mixed with the Rotor-Gene PCR SYBR Green mix and the reaction was performed in the Rotor-Gene Q instrument, following the PCR cycle: 10 sec at 96°C, 30 sec at 60°C, repeated 35 times. Primers NanoLuc RT-F-2 and NanoLucRT-R-2 were designed to amplify a 133 bp sequence of the NanoLuc sequence. Primers Pk-Aldolase-F-2 and Pk-Aldolase-R were designed to amplify a 147 bp sequence of the single copy gene *Pk aldolase* (access number: PKNH_1237500.1). The threshold cycle value (Ct) for each gene fragment was used to estimate the Δ Ct of each sample compared

with that of the single copy gene *Pk aldolase*, and the $\Delta\Delta Ct$ (36) was used to calculate relative proportions of NanoLuc copies in the different samples.

The samples used in this analysis were collected from *in vitro* cultures containing 1 nM WR99210 (Jacobus Pharmaceuticals, Princeton, NJ) for selective pressure, without drug pressure for 14 days, and from two infected rhesus macaques (rhesus #1 and rhesus #2). One sample was collected at day four of the first infection (rhesus #1) and the second sample was collected at day six of the second infection (rhesus #2). The *in vitro* culture sample under drug pressure was used as reference sample.

Antimalarial half-maximum inhibitory concentration (IC₅₀) determinations

Blood-stage *P. knowlesi* cultures were diluted to 0.5% parasitemia and brought to 2% hematocrit for growth in 96-well plates containing the desired drug concentration series (200 μ L of culture/well). Plates were incubated for 40 h at 37°C in a humidified chamber containing 5% CO₂, 5% O₂, and 90% N₂. Parasite growth in the plates was determined by quantification of double stranded DNA in each well (SYBR Green method) (37) or by the luminescence measured in each well (NanoLuc method).

For the SYBR Green method, the plates were removed from the incubator and frozen overnight. DNA amounts representing parasite growth were quantified by the SYBR Green I intercalating fluorescent dye (Life Technologies) as described (38). Plates were protected from light during the dye incubation period (30 – 60 min) and fluorescence intensities were measured using a FLUOstar Optima Microplate Reader (BMG Labtech,

Ortenberg, Germany) with excitation and emission settings of 485 nm and 535 nm, respectively.

For the NanoLuc method, plates were removed from the incubator and 100 μ L of NanoGlo IC₅₀ solution (Promega NanoGlo reaction mixture diluted 10-fold in PBS) were added to each well and mixed by pipetting. The plates were then incubated for 3 min at room temperature and the luminescence was assessed using a plate luminometer (Molecular Devices, San Jose, CA, USA) with 1 sec integration time. Fluorescence and luminescence readings were normalized to values from control wells containing no drug. IC₅₀ values were determined from fitted response curves (non-linear regression with variable slope, GraphPad Prism Software), and data from at least two independent assays were used to calculate the average IC₅₀ value of the *P. knowlesi* pvcen-pvhsp70-D-NanoLuc transgenic line with each method.

***Plasmodium knowlesi* red blood cell invasion assays**

P. knowlesi tightly synchronized schizonts were obtained by magnetic purification using MACS column (Miltenyi Biotec, Bergisch Gladbach, Germany) (39), adjusted to a 0.5% parasitemia in the target RBCs and incubated for 16 h at standard culture conditions. Rhesus RBCs were used as positive controls and mouse RBCs as negative controls. Invasion of human, *Aotus nancymae*, and *Saimiri boliviensis* RBCs was evaluated in the experiments. Invasion was determined by counting the number of ring-infected RBCs per 5,000 RBCs (microscopy counts), and expressed relative to the counts observed in rhesus RBCs (positive

control). Assay statistics were obtained from at least three independent experiments. For NanoLuc evaluation of RBC invasion, pvcen-pvhsp70-D-NanoLuc-transformed parasites were used for the invasion assays and the NanoLuc activity was assessed using the NanoGlo 20/20 luminometer as described above.

Results

P. vivax* 5' UTR are broadly active in *P. knowlesi* but limited in *P. falciparum

To evaluate the cross-species activity of different *Plasmodium* gene regulatory sequences, a variety of plasmids were constructed for expression of firefly luciferase (*fLuc*) under control of *P. vivax* or *P. falciparum* 5' UTR sequences. Plasmids pD-pvcam-Luc, pD-pvcrt-Luc and pD-pvhsp70-Luc contain 5' UTR sequences from the genes for *P. vivax* calmodulin (*pvcam*), chloroquine resistance transporter (*pvcrt*), and heat shock protein 70 (*pvhsp70*), respectively (**Fig 1**). Plasmid pD-pfcam-Luc (**Fig 1**) contains a 5' UTR sequence of the *P. falciparum* calmodulin gene (*pfcam*) and is a flanking region previously found to have cross-species promoter activity in *P. knowlesi* (10).

For measurements of luciferase activity, pRBC were taken from asynchronous *P. falciparum* or *P. knowlesi* cultures and transformed by introduction to culture with plasmid-loaded RBCs (spontaneous DNA uptake method) (10,35). **Fig 2** shows the relative luciferase levels from the different transfected parasite cultures normalized to the levels from parasites transfected with the plasmid pD-pfcam-Luc. Each of the four plasmid constructs yielded signals in *P. knowlesi* ranging from 0.5 to 4.4 × of the pD-pfcam-Luc signal. In

contrast, only two of the four plasmids provided luciferase signals in *P. falciparum*; no signals were obtained from *P. falciparum* parasites transfected with the *P. vivax* promoter constructs pD-pvcam-Luc and pD-pvcrt-Luc (**Fig 2, Supplementary Table 2**). These results are consistent with a previous report suggesting that *P. falciparum* is unable to recognize certain *P. vivax* promoters for expression (22). Nevertheless, *P. falciparum* parasites transfected with the plasmid pD-pvhs70-Luc presented luciferase levels similar to those from *P. knowlesi* transformants, 4.55 ± 0.18 -fold higher (average $\pm$ standard error of the mean) than the level from parasites transfected with the control plasmid pD-pfcam-Luc.

The *P. vivax* *hsp70* promoter sequence was also tested in *P. knowlesi* for expression of a drug resistance sequence used in selection of transgenic parasites. **Figure 1** presents schematics of the plasmids for this purpose: pvhs70D-pfcam-Luc contains the *pvhs70* promoter sequence driving *hdhfr* expression that confers resistance to antifolates such as WR99210 and pyrimethamine; pkef1D-pfcam-Luc contains the *pkef1-alpha* promoter previously used to drive *hdhfr* expression for selection of transgenic parasites *in vitro* (9). Both plasmids contain the *fLuc* reporter sequence under control of the *pfcam* promoter (**Fig 1**). **Fig 3A** shows the parasite growth observed by thin blood film microscopy in the cultures transfected with the different plasmids. Parasites were not detected by thin blood films in either culture 4 days after the start of drug selection with 1 nM WR99210, but they became detectable on day 14 (parasitemias = 0.1%) (**Supplementary Table 3**). **Fig 3B** shows the luciferase activity obtained from 80 μ L of RBCs collected from the cultures under selection. The luminescence signal of pvhs70D-pfcam-Luc transgenic parasites increased an average of 1.34-fold per day for the first 12 days under selection, similar to the pkef1D-pfcam-Luc

culture (average increase of 1.46 –fold/ day) (**Fig 3B, Supplementary Table 3**). Over a period of three weeks of drug pressure, the transformed parasites were observed to grow at a rate similar to untransfected cultures *in vitro* (3 – 5-fold/day; data not shown).

Rapid selection of transgenic parasites containing plasmids with *P. vivax* centromeric sequences

The inclusion of centromeric sequences in plasmids and artificial chromosomes can support maintenance of exogenous DNA in transfected parasites, with proper segregation through the multiple stages of their life cycle. Examples of success with this strategy have been reported with *P. berghei*, *P. falciparum*, and *Plasmodium cynomolgi* (40,41). To improve the maintenance and segregation of a selectable marker with very high sensitivity in detection assays, a plasmid containing *P. vivax* centromeric sequences (*pvcen*) was developed and tested in *Plasmodium yoelli* (34). Here, this plasmid was modified to generate *pvcen-pvhsp70-D-NanoLuc*, which expresses a fused-NanoLuc reporter cassette driven by the *P. vivax hsp70* promoter sequence (**Fig 1**).

P. knowlesi parasites were transfected with *pvcen-pvhsp70-D-NanoLuc* by the spontaneous DNA uptake method and drug-resistant parasites were selected by 1 nM WR99210 exposure. In three independent experiments, transgenic parasites containing the centromeric plasmid were detected after 8 days of drug pressure (parasitemia $\geq 0.1\%$) (**Fig 3C, Supplementary Table 4**), 6 days earlier than the detection of transgenic parasites containing episomal constructs without the centromeric sequences (**Fig 3A, Supplementary**

Table 3). In luminescence assays, parasites transfected with the centromeric plasmid presented an average reporter activity increase of 2.73-fold/day during eight days of drug selection (**Fig 3D, Supplementary Table 3**), greater than the rate of signal increase observed during selection of parasites transfected with the non-centromeric plasmid that also express *hdhfr* under control of the *pvhsp70* promoter (average increase of 1.34-fold/ day, **Fig 3B, Supplementary Table 3**). Over a period of two weeks' drug pressure, transgenic parasites were observed to have a growth rate similar to untransfected parasites (3 – 5-fold/day) and the NanoLuc signal increased linearly with the number of parasites (**Supplementary Table 4**). In serial dilution experiments, as few as 100 transformants could be detected by NanoLuc signal above background control from uninfected RBCs (**Supplementary Table 4**).

***P. knowlesi* transformed with a *P. vivax* centromere-containing reporter plasmid completes the parasite life cycle in rhesus macaques and *An. dirus* mosquitoes**

In experiments to evaluate the ability of pvcen-pvhsp70-D-NanoLuc transformants to complete the full life cycle while expressing NanoLuc *in vivo* under no drug selection pressure, the parasites were inoculated into a splenectomized rhesus macaque (rhesus #1). Parasites were observed in Giemsa-stained thin blood films at day 3 after inoculation (**Fig 4A, Supplementary Table 5**), after which parasitemia rapidly increased up to 2% at day 5. At midnight of day 5, when the rhesus parasitemia reached 1.23%, *An. dirus* B and *An. dirus* X mosquitoes (31) were fed on the infected monkey; the procedure was repeated the next

night at a similar parasitemia of 1.20% (**Fig 4A; Feeds #1 and #2**). Seven days after each feed, 16 – 20 mosquitoes were randomly selected from the individual batch for dissection and midgut isolation. As shown in **Fig 4B** and **Supplementary Table 6**, Feed #1 yielded a smaller number of infected mosquitoes (11 of 16 dissected) than Feed #2 (19 of 20 dissected). Oocyst counts per mosquito were also lower in Feed #1 than in Feed #2 (**Fig 4B**; 2.5 vs. 16.6 oocysts per mosquito on average, respectively). NanoLuc determinations from individual isolated midguts confirmed higher signals in proportion to the number of oocysts per midgut (**Fig 4C, Supplementary Table 6**) ($R^2 = 0.6903$).

At day 10 after the feeds, eight mosquitoes from each batch were randomly selected and dissected for salivary glands and sporozoite detection. Total sporozoites from each group were counted, and, as expected from the oocyst data, higher sporozoite numbers were observed in mosquitoes from Feed #2 than Feed #1 (29,688 vs. 5,953 sporozoites per mosquito on average, respectively); no significant difference was found between the *An. dirus* B and *An. dirus* X strains (**Supplementary Table 7**). NanoLuc activity was correspondingly higher from the greater number of sporozoites in Feed #2 mosquitoes (**Fig 4D; Supplementary Table 7**) ($R^2 = 0.9516$).

The remaining sporozoite-infected mosquitoes were used to infect a second non-naïve macaque (rhesus #2). Six days after the mosquito bites and sporozoite injection, parasites were detected in Giemsa-stained thin blood films of peripheral blood (**Fig 4E; Supplementary Table 5**). Development of the infection was similar to previous reports of rhesus infections using sporozoites (via mosquito bites) (31,42). NanoLuc activity was

readily detected in blood samples, even when taken at a low 0.03% parasitemia (data not shown).

Centromeric plasmids are present at reduced number in transformed parasites that complete the full life cycle without drug selection

During the course of rhesus macaque infection #1, transmission to mosquitoes, and infection of rhesus macaque #2, the pvcen-pvhsp70-D-NanoLuc transformants were not subjected to drug pressure. To assess the plasmid maintenance over the life cycle in this absence of drug selection, including mitosis during the asexual parasite multiplication and meiosis after zygote formation, DNA was extracted from parasite samples and qPCR analysis was performed to quantify copy number of the NanoLuc cassette relative to the endogenous chromosome copy of the *aldolase* gene. The results indicated plasmid copy number loss during *in vivo* infections: parasites isolated from rhesus #1 at infection day 4 presented only half of the plasmid copy numbers of the parasites from *in vitro* cultures maintained for 14 days without drug pressure (**Fig 4F, Supplementary Table 8**). Parasites isolated from rhesus #2 at infection day 6, showed a 20-fold plasmid copy number loss compared to parasites from the unpressured *in vitro* culture. In marked contrast, parasites from the *in vitro* cultures showed no plasmid copy number loss relative to the *aldolase* gene after 14 days without drug pressure (**Supplementary Table 8**).

NanoLuc facilitates high-throughput assays of anti-malarial compounds and parasite invasion

To evaluate for potential use of NanoLuc-transformed *P. knowlesi* line in assays of antimalarial compounds, IC₅₀ drug response measures assessed by NanoLuc signals were compared to the measures from standard SYBR Green assays. Results were obtained from transgenic and non-transgenic (“wild-type”) parasites exposed to chloroquine, WR99210, and G418 (**Table 1, Supplementary Table 9**). No significant differences were observed between the IC₅₀ values from the two methods, and *P. knowlesi* transformants presented chloroquine and G418 IC₅₀ values similar to untransfected parasites (**Table 1, Supplementary Table 9**). WR99210 IC₅₀ values of the transformants were about 100-fold higher, consistent with *hdhfr* expression from the pvcen-pvhsp70-D-NanoLuc plasmid.

Table 1. Antimalarial half-maximum inhibitory concentration (IC₅₀) values obtained by SYBR Green and NanoLuc assays

<i>P. knowlesi</i> parasite line	Drug	SYBR Green method			NanoLuc method		
		IC ₅₀	SEM	N	IC ₅₀	SEM	N
H strain (untransfected)	chloroquine	17.06 nM	1.82*	2	NA	NA	NA
	WR99210	0.07 nM	0.01	3	NA	NA	NA
	G418	213.85 µM	60.17*	2	NA	NA	NA
pvcen-pvhsp70-D-	chloroquine	16.81 nM	1.91	3	16.13 nM	1.54	4
NanoLuc	WR99210	6.59 nM	1.54	3	7.36 nM	2.14	5

G418 270.80 μ M 57.13* 2 239.63 μ M 22.59 3

N: Number of independent biological replicates performed. SEM: Standard Error of the Mean. *Standard Error is presented for the IC₅₀ values obtained using two biological replicates. NA: not applicable.

Invasion assays were also performed using NanoLuc-transformed parasites. Tightly synchronized *in vitro*-cultivated *P. knowlesi* schizonts were used to invade RBCs from different animal sources – rhesus macaque, human, *Aotus nancymae*, *Saimiri boliviensis* and mouse. **Table 2** and **Supplementary Table 10** show that no significant difference in the results was observed between the Giemsa-stained thin blood film counts and the luminescence activity of the NanoLuc-transformed parasites, confirming that luminescence can be used to evaluate invasion of RBCs.

Table 2. *Plasmodium knowlesi* pvcen-pvhsp70-D-NanoLuc red blood cell invasion, determined by microscopy and NanoLuc activity

	Microscopy			NanoLuc method	
RBC source	RBC invasion	SEM	N	RBC invasion	N
	relative to rhesus			relative to rhesus	
	RBCs			RBCs	
Human	0.74	0.11	3	0.84	1

<i>Aotus nancymae</i>	0.53	0.04	3	0.34	1
<i>Saimiri boliviensis</i>	0.34	0.01	3	0.40	1
mouse	0.03	0.02	3	0.06	1

N: Number of independent biological replicates performed. SEM: Standard Error of the Mean.

Discussion

Previous evaluations of *P. vivax* regulatory sequences in *P. falciparum* showed that many were inactive (22), suggesting significant differences in the utilization of promoter elements by these species. The *P. vivax* 5' UTRs studied in this work functioned in *P. knowlesi* even though some were inactive in *P. falciparum*. The 5' UTRs of *pvcam* and *pvcrt* are two examples of flanking regions capable of driving the fLuc in *P. knowlesi* but not in *P. falciparum*. In contrast, the 5' UTR of *pvhsp70* has activity in both parasites, driving at least 4-fold greater expression than the control *pfcam* 5'UTR. The longer length of the *pvhsp70* 5'UTR (1.4 Kb) may contribute for this stronger promoter activity. Highly conserved promoter elements in the *P. vivax* heat-shock gene evidently support similar levels of transcription in transformed *P. knowlesi* and *P. falciparum* parasites. In this regard, the presence of five copies of a GCATAT element in the 5' UTR of *pvhsp70* may be relevant as this element has been identified as a feature of some deeply conserved genes in divergent branches of *Plasmodium* evolution (22). Absence of GCATAT from the 5' UTRs of *pvcam* and

pvcrt is consistent with less conserved promoters that are operative in both *P. knowlesi* and *P. vivax* but are not recognized in *P. falciparum*.

Episomal plasmids replicate by a rolling-circle mechanism leading to the formation of concatemers, resulting in variable copy numbers of the plasmid (43) and wide ranges of reporter expression. Furthermore, while episomal plasmids are useful tools for genetic studies; their maintenance requires drug pressure to prevent plasmid loss during cell division. To obviate these difficulties with copy numbers and generate transgenic lines that express reporter sequences through the complete parasite life cycle, plasmids containing centromeric sequences have been developed and used in *P. berghei*, *P. yoelii*, *P. falciparum*, and *P. cynomolgi* (34,40,43,44). Previous reports showed transgenic parasites containing centromeric plasmids were selected faster than parasites transfected with regular episomal constructs (34,40). Therefore, in the present study cultivated *P. knowlesi* parasites were transfected with the *pvcen-pvhsp70-D-NanoLuc* plasmid that contains *P. vivax* centromeric sequences and an *hdhfr* selection cassette. The resulting parasites expanded more than twice as fast as transformants containing non-centromeric plasmids, consistent with improved segregation and maintenance of the centromeric plasmid. Expression of the ultra-bright NanoLuc reporter sequence was confirmed throughout the *in vivo* life cycle, in blood-stage parasites, oocysts and sporozoites, and this expression was linearly related to the number of parasites in the assays. This linearity is an advantage of centromeric plasmids, that has been exploited successfully in mosquito stages, allowing its use in studies of mosquito-stage gene control and transmission blocking strategies (40). However, without drug selection, the episomal plasmid showed copy number loss over the life cycle,

particularly *in vivo*. This finding highlights an advantage of transgenic lines that contain reporter sequences integrated into chromosomes of the parasite genome, achievable for example by recently developed zinc-finger gene modification methods (45,46) or by CRISPR/Cas9 technology (47,48). Whether the persistence of centromere-containing plasmids in *P. knowlesi* can be improved by use of homologous *pkcen* instead of *pvcen* elements remains to be investigated.

Rapid assay determinations and sensitivity allowing the use of low parasite numbers are among the advantages of NanoLuc-expressing parasites for high-throughput screening platforms. In the present work, NanoLuc expressing *P. knowlesi* were successfully used in drug response tests of blood-stage parasites *in vitro*, and the IC₅₀ values obtained by luminescence assays were comparable to IC₅₀ values obtained by the SYBR green method. Additionally to their use in drug response, centromeric plasmids such as *pvcen-pvhsp70-D-NanoLuc* may be useful in other experimental applications such as *in vivo* imaging. The *P. knowlesi* transformants can also be useful for validation of plasmid constructs prior to their use in transfection of *P. vivax*, which requires expensive non-human primate resources. The ultrabright and stable NanoLuc reporter has been previously used in *P. falciparum* (49) and *P. berghei* (29,50), producing luminescence up to 150-fold higher than firefly luciferase, and enabling detection of parasites at low densities and as single sporozoite (50). Recently developed methods of mosquito infection from *in vitro* *P. knowlesi* cultures (11) may thus provide useful strategies in high-sensitivity screens for transmission blocking vaccines and inhibitors of liver-stage parasites (29,49,50).

Conclusions

P. knowlesi parasites can drive expression *P. vivax* promoters that are poorly recognized by *P. falciparum*, consistent with the closer evolutionary relationship of *P. vivax* to *P. knowlesi* than to *P. falciparum*. However, more conserved promoters like that of *pvhsp70* retain similar recognition by *P. vivax* and *P. falciparum*. Centromeric sequences from *P. vivax* can improve the efficiency of genetic transformation and may promote the stability of transfected plasmids across the complete *P. knowlesi* life cycle, through rhesus monkeys and *An. dirus* mosquitoes. NanoLuc-expressing, centromere-stabilized plasmids may be useful for high-throughput antimalarial screenings as well as biological imaging of *P. knowlesi* in the mosquito and vertebrate hosts.

Declarations

Ethics approval and consent to participate

All Non-human primate care and use in this study were performed in accordance with the NIH Animal Research Advisory Committee (NIH ARAC) Guidelines, under an Animal Study Proposal approved by the NIAID Animal Care and Use Committee (NIAIDLMIIV 9E).

Consent for publication

Not Applicable

Availability of data and materials

All data generated or analyzed in this study are provided in the main text of this published article or as additional files.

Competing interests

The authors declare that they have no competing interests.

Funding

This study was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health and Bill & Melinda Gates Foundation (OPP1023643 to JHA.), Grants-in-Aid for Scientific Research 23659215 (OK), MEXT, Japan and CNPq Universal Grant (434011/2018-5) and FAPESP JP award 2018/06219-8 (RMB), Brazil. This work was partly conducted at the Joint Usage / Research Center for Tropical Disease, Institute of Tropical Medicine, Nagasaki University, Japan.

Authors' contributions

RMB, JSA, JMS, JHA, OK and TEW designed the study. RMB, KT, JSA, TJG, RLC, MK, WAK, JPM, JKB, TE, LL, SOG performed experiments. RMB, JSA, TJG, JMS and TEW wrote the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We thank Patrick E. Duffy for providing the *P. knowlesi* H strain, rhesus blood samples for *in vitro* cultivation of parasites, and animal infections; Billela Lewis, Milton J. Herrera, and Kelly E. Dicken, for monkey care; and Andre Laughinghouse and Kevin L. Lee, for providing and maintaining mosquitoes.

Additional Files

Additional file 1.

Additional_file_1.xls

Supplementary tables

Supplementary Table 1. Oligonucleotide primers used in this work

Supplementary Table 2. Transient transfection of *Plasmodium* parasites

Supplementary Table 3. *Plasmodium knowlesi* growth and luminescence signal during selection using WR99210

Supplementary Table 4. NanoLuc signal of *in vitro* cultivated transgenic blood-stage parasites

Supplementary Table 5. Rhesus infections with transgenic luminescent *P. knowlesi*

Supplementary Table 6. Number of oocysts detected in individual mosquitoes dissected 7 days after the feeds and Luminescence signals obtained (only midguts isolated from mosquitoes from Feed #2)

Supplementary Table 7. Total sporozoites isolated from 8 mosquitoes from each species, infected with transgenic bioluminescent *P. knowlesi*, 10 days after the feeds and Luminescence signals

Supplementary Table 8. pvcen-pvhsp70-D-NanoLuc plasmid copy number variation in blood-stage parasites

Supplementary Table 9. Half-maximum inhibitory concentration (IC_{50}) measures of drug response

Supplementary Table 10. *Plasmodium knowlesi* red blood cell invasion assays

References

1. Yusof R, Lau YL, Mahmud R, Fong MY, Jelip J, Ngian HU, et al. High proportion of knowlesi malaria in recent malaria cases in Malaysia. *Malar J.* 2014;13(1):1–9.
2. Singh B, Daneshvar C. Human infections and detection of *Plasmodium knowlesi*. *Clin Microbiol Rev.* 2013;26(2):165–84.
3. William T, Jelip J, Menon J, Anderios F, Mohammad R, Awang Mohammad TA, et al. Changing epidemiology of malaria in Sabah, Malaysia: Increasing incidence of *Plasmodium knowlesi*. *Malar J.* 2014;13(1):1–11.
4. William T, Rahman HA, Jelip J, Ibrahim MY, Menon J, Grigg MJ, et al. Increasing Incidence of *Plasmodium knowlesi* Malaria following Control of *P. falciparum* and *P. vivax* Malaria in Sabah, Malaysia. *PLoS Negl Trop Dis.* 2013;7(1).
5. WHO. World malaria report 2017. [Internet]. Geneva: World Health Organization; 2017: Licence: CC BY-NC-SA 3.0 IGO.; 2017. Available from: <http://apps.who.int/iris/bitstream/10665/259492/1/9789241565523-eng.pdf?ua=1>
6. Trager W, Jensen JB. Human malaria parasites in continuous culture. *Science* (80-). 1976;193(4254):673–5.
7. Butcher GA, Mitchell GH. The role of *Plasmodium knowlesi* in the history of malaria research. *Parasitology.* 2016;1–12.
8. Kocken CHM, Ozwara H, Van der Wel A, Beetsma AL, Mwenda JM, Thomas AW. *Plasmodium knowlesi* provides a rapid in vitro and in vivo transfection system that

enables double-crossover gene knockout studies. *Infect Immun*. 2002;70(2):655–60.

9. Moon RW, Hall J, Rangkuti F, Ho YS, Almond N, Mitchell GH, et al. Adaptation of the genetically tractable malaria pathogen *Plasmodium knowlesi* to continuous culture in human erythrocytes. *Proc Natl Acad Sci [Internet]*. 2013;110(2):531–6. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.1216457110>
10. Moraes Barros RR, Gibson TJ, Kite WA, Sá JM, Wellems TE. Comparison of two methods for transformation of *Plasmodium knowlesi*: Direct schizont electroporation and spontaneous plasmid uptake from plasmid-loaded red blood cells. *Mol Biochem Parasitol [Internet]*. 2017;218(January):16–22. Available from: <http://dx.doi.org/10.1016/j.molbiopara.2017.10.001>
11. Armistead JS, Moraes Barros RR, Gibson TJ, Kite WA, Mershon JP, Lambert LE, et al. Infection of mosquitoes from in vitro cultivated *Plasmodium knowlesi* H strain. *Int J Parasitol*. 2018;
12. Hawking F, Worms MJ, Gammage K. Host Temperature and Control of 24-Hour and 48-Hour Cycles in Malaria Parasites. *Lancet [Internet]*. 1968;291(7541):506–9. Available from: <http://www.sciencedirect.com/science/article/pii/S0140673668914694>
13. Rijo-Ferreira F, Acosta-Rodriguez VA, Abel JH, Kornblum I, Bento I, Kilaru G, et al. The malaria parasite has an intrinsic clock. *Science (80-) [Internet]*. 2020 May 15 [cited 2020 Oct 2];368(6492):746–53. Available from: <https://pubmed.ncbi.nlm.nih.gov/32409471/>

14. Adams JH, Sim BK, Dolan SA, Fang X, Kaslow DC, Miller LH. A family of erythrocyte binding proteins of malaria parasites. *Proc Natl Acad Sci* [Internet]. 1992;89(15):7085–9. Available from: <http://www.pnas.org/cgi/doi/10.1073/pnas.89.15.7085>
15. Hayton K, Gaur D, Liu A, Takahashi J, Henschen B, Singh S, et al. Erythrocyte Binding Protein PfRH5 Polymorphisms Determine Species-Specific Pathways of *Plasmodium falciparum* Invasion. *Cell Host Microbe*. 2008;4(1):40–51.
16. Cowman AF, Tonkin CJ, Tham W-H, Duraisingh MT. The Molecular Basis of Erythrocyte Invasion by Malaria Parasites. *Cell Host Microbe* [Internet]. 2017 Aug 9 [cited 2018 May 21];22(2):232–45. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/28799908>
17. Gautret P, Motard A. Periodic infectivity of *Plasmodium* gametocytes to the vector. A review. *Parasite*. 1999;6(2):103–11.
18. Chotivanich K, Udomsangpetch R, Chierakul W, Newton PN, Ruangveerayuth R, Pukrittayakamee S, et al. In vitro efficacy of antimalarial drugs against *Plasmodium vivax* on the western border of Thailand. *Am J Trop Med Hyg*. 2004;70(4):395–7.
19. Nomura T, Carlton JM, Baird JK, del Portillo HA, Fryauff DJ, Rathore D, et al. Evidence for different mechanisms of chloroquine resistance in 2 *Plasmodium* species that cause human malaria. *J Infect Dis*. 2001;183(11):1653–61.
20. Amino R, Thiberge S, Martin B, Celli S, Shorte S, Frischknecht F, et al. Quantitative imaging of *Plasmodium* transmission from mosquito to mammal. *Nat Med*. 2006;

21. Deitsch KW, Calderwood MS, Wellems TE. Malaria. Cooperative silencing elements in var genes. Nature [Internet]. 2001;412(6850):875–6. Available from: <http://dx.doi.org/10.1038/35091146><http://www.ncbi.nlm.nih.gov/pubmed/11528468><http://www.nature.com/nature/journal/v412/n6850/abs/412875b0.html>
22. Azevedo MF, Del Portillo HA. Promoter regions of Plasmodium vivax are poorly or not recognized by Plasmodium falciparum. Malar J. 2007;6.
23. Calderwood MS, Gannoun-Zaki L, Wellems TE, Deitsch KW. Plasmodium falciparum var Genes Are Regulated by Two Regions with Separate Promoters, One Upstream of the Coding Region and a Second within the Intron. J Biol Chem. 2003;278(36):34125–32.
24. De Koning-Ward TF, Sperança MA, Waters AP, Janse CJ. Analysis of stage specificity of promoters in Plasmodium berghei using luciferase as a reporter. Vol. 100, Molecular and Biochemical Parasitology. 1999. p. 141–6.
25. De Niz M, Helm S, Horstmann S, Annoura T, Del Portillo HA, Khan SM, et al. In vivo and in vitro characterization of a Plasmodium liver stage-specific promoter. PLoS One. 2015;10(4).
26. Hasenkamp S, Sidaway A, Devine O, Roye R, Horrocks P. Evaluation of bioluminescence-based assays of anti-malarial drug activity. Malar J [Internet]. 2013 Feb 8 [cited 2018 May 21];12(1):58. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/23394077>

27. Swann J, Corey V, Scherer CA, Kato N, Comer E, Maetani M, et al. High-Throughput Luciferase-Based Assay for the Discovery of Therapeutics That Prevent Malaria. ACS Infect Dis [Internet]. 2016 Apr 8 [cited 2018 May 21];2(4):281–93. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27275010>
28. Lin JW, Sajid M, Ramesar J, Khan SM, Janse CJ, Franke-Fayard B. Screening inhibitors of *P. berghei* blood stages using bioluminescent reporter parasites. Methods Mol Biol. 2013;
29. Calit J, Dobrescu I, Gaitán XA, Borges MH, Ramos MS, Eastman RT, et al. Screening the Pathogen Box against *Plasmodium* sexual stages using a new nanoluciferase based transgenic line of *P. berghei* identifies transmission-blocking compounds. Antimicrob Agents Chemother. 2018;
30. Walliker D, Quakyi IA, Wellems TE, McCutchan TF, Szarfman A, London WT, et al. Genetic analysis of the human malaria parasite *Plasmodium falciparum*. Science (80-). 1987;
31. Murphy JR, Weiss WR, Fryauff D, Dowler M, Savransky T, Stoyanov C, et al. Using infective mosquitoes to challenge monkeys with *Plasmodium knowlesi* in malaria vaccine studies. Malar J. 2014;13(1):1–11.
32. Zeeman AM, Voorberg-Van Der Wel A, Kocken CHM. Ex vivo culture of *plasmodium vivax* and *plasmodium cynomolgi* and in vitro culture of *plasmodium knowlesi* blood stages. Methods Mol Biol. 2013;
33. Sá JM, Kaslow SR, Moraes Barros RR, Brazeau NF, Parobek CM, Tao D, et al.

Plasmodium vivax chloroquine resistance links to pvcrt transcription in a genetic cross. Nat Commun [Internet]. 2019 Dec 1 [cited 2020 Oct 5];10(1). Available from: <https://pubmed.ncbi.nlm.nih.gov/31541097/>

34. Thawnashom K, Kaneko M, Xangsayarath P, Chaiyawong N, Yahata K, Asada M, et al. Validation of *Plasmodium vivax* centromere and promoter activities using *Plasmodium yoelii*. PLoS One. 2019;14(12).
35. Deitsch K, Driskill C, Wellems T. Transformation of malaria parasites by the spontaneous uptake and expression of DNA from human erythrocytes. Nucleic Acids Res. 2001;29(3):850–3.
36. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2- $\Delta\Delta$ CT method. Methods. 2001;25(4):402–8.
37. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M. Simple and Inexpensive Fluorescence-Based Technique for High-Throughput Antimalarial Drug Screening. Antimicrob Agents Chemother. 2004;48(5):1803–6.
38. Johnson JD, Denuil RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC. Assessment and continued validation of the malaria SYBR Green I-based fluorescence assay for use in malaria drug screening. Antimicrob Agents Chemother. 2007;51(6):1926–33.
39. Ribaut C, Berry A, Chevalley S, Reybier K, Morlais I, Parzy D, et al. Concentration and purification by magnetic separation of the erythrocytic stages of all human *Plasmodium* species. Malar J. 2008;

40. Iwanaga S, Khan SM, Kaneko I, Christodoulou Z, Newbold C, Yuda M, et al.
Functional Identification of the Plasmodium Centromere and Generation of a
Plasmodium Artificial Chromosome. *Cell Host Microbe*. 2010;7(3):245–55.
41. Voorberg-van der Wel A, Zeeman AM, van Amsterdam SM, van den Berg A, Klooster
EJ, Iwanaga S, et al. Transgenic Fluorescent Plasmodium cynomolgi Liver Stages
Enable Live Imaging and Purification of Malaria Hypnozoite-Forms. *PLoS One*.
2013;8(1).
42. Mahdi Abdel Hamid M, Remarque EJ, El Hassan IM, Hussain AA, Narum DL, Thomas
AW, et al. Malaria infection by sporozoite challenge induces high functional
antibody titres against blood stage antigens after a DNA prime, poxvirus boost
vaccination strategy in Rhesus macaques. *Malar J*. 2011;
43. Williamson DH, Janse CJ, Moore PW, Waters AP, Preiser PR. Topology and
replication of a nuclear episomal plasmid in the rodent malaria Plasmodium
berghei. *Nucleic Acids Res [Internet]*. 2002;30(3):726–31. Available from:
<http://nar.oxfordjournals.org/content/30/3/726.abstract>
44. Voorberg-van der Wel AM, Zeeman AM, Nieuwenhuis IG, van der Werff NM,
Klooster EJ, Klop O, et al. A dual fluorescent Plasmodium cynomolgi reporter line
reveals in vitro malaria hypnozoite reactivation. *Commun Biol*. 2020;
45. Barros RRM, Straimer J, Sa JM, Salzman RE, Melendez-Muniz VA, Mu J, et al. Editing
the plasmodium vivax genome, using zinc-finger nucleases. *J Infect Dis*.
2015;211(1):125–9.

46. Straimer J, Lee MCS, Lee AH, Zeitler B, Williams AE, Pearl JR, et al. Site-specific genome editing in *Plasmodium falciparum* using engineered zinc-finger nucleases. *Nat Methods*. 2012;9(10):993–8.
47. Ghorbal M, Gorman M, MacPherson CR, Martins RM, Scherf A, Lopez-Rubio JJ. Genome editing in the human malaria parasite *Plasmodium falciparum* using the CRISPR-Cas9 system. *Nat Biotechnol*. 2014;32(8):819–21.
48. Mohring F, Hart MN, Rawlinson TA, Henrici R, Charleston JA, Diez Benavente E, et al. Rapid and iterative genome editing in the malaria parasite *Plasmodium knowlesi* provides new tools for *P. vivax* research. *Elife*. 2019;
49. Azevedo MF, Nie CQ, Elsworth B, Charnaud SC, Sanders PR, Crabb BS, et al. *Plasmodium falciparum* transfected with ultra bright nanoluc luciferase offers high sensitivity detection for the screening of growth and cellular trafficking inhibitors. *PLoS One*. 2014;9(11).
50. De Niz M, Stanway RR, Wacker R, Keller D, Heussler VT. An ultrasensitive NanoLuc-based luminescence system for monitoring *Plasmodium berghei* throughout its life cycle. *Malar J* [Internet]. 2016;15(1):232. Available from: <http://www.ncbi.nlm.nih.gov/pubmed/27102897><http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC4840902>

Figures

Figure 1. Plasmid constructs used to evaluate *Plasmodium* promoter sequences in *P. knowlesi*. Expression of *hdhfr* from the plasmids confers resistance to WR99210 and a *fLuc* or *Nanoluc* reporter. The pD-pfcam-Luc plasmid has the *fLuc* cassette driven by the *P. falciparum calmodulin* 5' UTR (*pfcam* 5') and the *hdhfr* cassette driven by the *P. chabaudi dts* 5' UTR (*pcdts* 5'). pD-pvcam-Luc, pD-pvcrt-Luc and pD-pvbsp70-Luc have the 5' UTR sequences of *P. vivax calmodulin* (*pvcam* 5'), *chloroquine resistance transporter* (*pvcrt* 5') and *heat shock protein 70* (*pvbsp70* 5') driving *fLuc* expression, respectively, replacing the *pfcam* promoter from the pD-pfcam-Luc. Plasmids pvbsp70D-pfcam-Luc and pkef1D-pfcam-

Luc have the 5' UTR sequences of *P. vivax* heat shock protein 70 (*pvhsp70* 5') and *P. knowlesi* elongation factor 1 α (*pkef1- α* 5'), respectively, replacing the *pcdts* promoter from the pD-pfcam-Luc to drive the expression of *hdhfr*. The pvcen-pvhsp70-D-NanoLuc plasmid includes *P. vivax* centromeric sequence repeats from chromosome 11 (*Pv centromeric repeats*) and has *hdhfr*-NanoLuc fusion expression driven by the *P. vivax* heat shock protein 70 5' UTR (*pvhsp70* 5'). The arrows indicate directions of transcription.

Figure 2. *P. knowlesi* recognizes *P. vivax* promoter regions not recognized by *P. falciparum*. *P. falciparum* and *P. knowlesi* parasites were transformed *in vitro* by spontaneous DNA uptake from RBCs pre-loaded with plasmids pD-pfcam-Luc, pD-pvcam-Luc, pD-pvcrt-Luc, or pD-pvhsp70-Luc. Luciferase activity measurements were obtained after 72 h of parasite cultivation in the plasmid-loaded RBCs and were normalized relative to the activity obtained from parasites transformed with pD-pfcam-Luc. Values represent the mean $\pm$ standard error from three independent experiments.

Figure 3. Selection of drug-resistant *P. knowlesi* harboring markers under the control of *P. vivax* regulatory sequences. Drug selection with 1 nM WR99210 was initiated 72 h after addition of plasmid-loaded RBCs to parasite cultures. (A) Parasitemia counts by microscopy of cultures transfected with plasmids pvhsp70D-pfcam-Luc and pkef1D-pfcam-Luc over 16 days of drug selection. (B) Luminescence measurements from samples of the transformant cultures presented in Fig 3A. (C) Parasitemia counts by microscopy of cultures transfected with plasmid pvcen-pvhsp70-D-NanoLuc in three independent experiments. (D) Luminescence measurements from samples of the transformant cultures presented in Fig 3C. LUs, luminescence units; mock, control transformation experiments performed in parallel without plasmid; parasitemia, percentage of RBCs infected with *P. knowlesi* parasites (counts of 1,000 RBCs).

Figure 4. Bioluminescent *P. knowlesi* transformants complete the parasite life cycle *in vivo*. (A) Development of blood stage parasitemia in a splenectomized non-naïve rhesus macaque (rhesus #1) infected with pvcn-pvhs70-D-NanoLuc-transformed *P. knowlesi*. The red arrows indicate when mosquito feedings were performed; blue arrows indicate administration of chloroquine (50 mg/kg, oral). (B) Counts of oocysts in the mosquito

midgut 7 days after blood feeding. (C) NanoLuc activities from midguts isolated from Feed #2 infected mosquitoes. (D) NanoLuc activities from sporozoites isolated from mosquitoes 10 days after either Feed #1 or Feed #2 on rhesus macaque DCID. (E) Blood stage parasitemia developed in a splenectomized non-naïve rhesus macaque (rhesus #2) after bites of mosquitoes carrying infectious sporozoites. The blue arrows indicate chloroquine treatments (50 mg/kg, oral). (F) Copy numbers of the NanoLuc coding sequence relative to those of the single-copy *P. knowlesi aldolase* gene in blood-stage parasites from *in vitro* cultures and from blood samples of rhesus monkeys #1 and #2. Copy number results from each sample are presented relative to the copy number of pvcen-pvhsp70-D-NanoLuc-transformed *P. knowlesi* parasites cultivated under WR99210 selection pressure (black); cultivated parasites maintained 14 days *in vitro* without drug pressure (gray); parasites from rhesus #1 (blue); parasites from rhesus #2 (red). Error bars represent standard error of the mean; LUs, Luminescence units.